Antitumour T cells stand the test of time

Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade

(2019) Brian C. Miller et al.   NATURE IMMUNOLOGY

Targeting REGNASE-1 programs long-lived effector T cells for cancer therapy

(2019) Jun Wei et al.   NATURE

Metabolic Control of CD8 + T Cell Fate Decisions and Antitumor Immunity

(2018) Lianjun Zhang et al.   TRENDS IN MOLECULAR MEDICINE

In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target

(2017) Robert T. Manguso et al.   NATURE

The Tumor Microenvironment Represses T Cell Mitochondrial Biogenesis to Drive Intratumoral T Cell Metabolic Insufficiency and Dysfunction

(2016) Nicole E. Scharping et al.   IMMUNITY

The transcription factor BATF operates as an essential differentiation checkpoint in early effector CD8+ T cells

(2014) Makoto Kurachi et al.   NATURE IMMUNOLOGY

Malt1-Induced Cleavage of Regnase-1 in CD4+ Helper T Cells Regulates Immune Activation

(2013) Takuya Uehata et al.   CELL

The IκB kinase complex regulates the stability of cytokine-encoding mRNA induced by TLR–IL-1R by controlling degradation of regnase-1

(2011) Hidenori Iwasaki et al.   NATURE IMMUNOLOGY

Zc3h12a is an RNase essential for controlling immune responses by regulating mRNA decay

(2009) Kazufumi Matsushita et al.   NATURE